To study somatostatin/dopamine (SS/D) synergy in a human cell system constitutively expressing SS and D receptors (SSR, DR), we characterized the expression of SSR and DR subtypes in the non-small cell lung cancer line CALU-6 and then we evaluated the effect on cell proliferation of SS/D chimeric molecules (BIM-23A387 and BIM-23A370), which bind with high affinity both sst 2 and D 2 R, and compared the results with those obtained using SS-14 and subtype-selective SS analogs (SSA) and D agonists (DA). Since CALU-6 cells produce IGF and IGFBP peptides, which play a role in the autocrine/paracrine control of cell growth, we also investigated the effects of chimeric compounds on secretion and expression of IGF system components. Relative high levels of sst 2, as well as the long isoform of the D 2 R were detected by real-time RT-PCR and Western blot in CALU-6, together with sst 5 and to a lesser extent sst 3 and D 4 R. BIM-23A387 and BIM-23A370 significantly inhibited growth of CALU-6, whereas IGF-IGFBP secretion or expression were unaffected, suggesting a direct inhibitory effect. The inhibition of cell growth, measured by both 3 H-thymidine incorporation and cell count, was significantly lower when individual SSA and DA control peptides, or subtype-specific SSA and DA were tested. BIM-23A370 was more potent than BIM23A387 (p<0.001). These findings show that SS/D chimeras can inhibit CALU-6 proliferation in an IGF-independent manner, and suggest that this enhanced potency might be due the induction of SSR/DR dimerization. CALU-6 cell line, constitutively expressing SSR and DR, provides a suitable model to elucidate the mechanism of action of SSA and DA upon regulation of cell growth, and to characterize the interaction between SSR and DR.
INTRODUCTION
Somatostatin (SS) plays an important regulatory role in controlling the function of various cells, including inhibition of hormone release, immunomodulation, neurotransmission and inhibition of cell proliferation and angiogenesis (8, 2). Most of the effects of SS and of its currently available analogs (SSA), octreotide, lanreotide and vapreotide, are mediated via a family of high-affinity G protein-coupled membrane receptors (SSR) with five known subtypes, termed sst [1] [2] [3] [4] [5] (15) . All the genes for SSR are intronless except the sst 2 , which contains a cryptic intron sequence and encodes for two receptor proteins, sst 2A and sst 2B , which originate from alternative splicing. SSR are expressed in a tissue-and subtype-selective manner in both normal and neoplastic cells, and the majority of SS-target tissues express multiple SSR subtypes at the same time (21, 29) .
Similarly, 5 different dopamine receptors (D 1-5 R), also belonging to the G protein-coupled family of receptors, have been cloned and characterized so far (12) . Alternative splicing of the gene encoding the D 2 R leads to the short (D 2 Rs) or the long (D 2 Rl) isoforms. SSA and new potent dopamine agonists (DA), such as cabergoline and quinagolide, are routinely used, alone or in combination, for medical treatment of pituitary adenomas. These compounds not only inhibit hormone secretion, but can also reduce tumor mass (27) . Moreover, recent data suggest that membrane SSR and DR may interact to form heterodimers with enhanced functional activity (23) . However, receptor dimerization has thus far only been demonstrated in transfected cell systems and in rat neuronal cells (1) . It is of great interest to investigate whether such a phenomenon occurs in human cells constitutively co-expressing SSR and DR. Recently, SS/DA chimeric molecules were created that contain structural elements of both SS and D. These hybrid molecules retain potent, selective agonist activity on both the sst 2 and the D 2 R, and their activities are currently being investigated in different cell systems (20, 26) .
Human small cell lung cancer (SCLC) and non-SCLC (NSCLC) may express SSR to a greater extent than normal tissue, as has been demonstrated both in vivo and in vitro (13, 16, 18,) .
Interestingly, DR are expressed in human lung tumor as well, and DA has been shown to inhibit the growth of human SCLC xenografts in athymic nude mice in a dose-dependent manner (7, 28).
CALU-6 is an established human NSCLC cell line producing a large amount of IGF-II, a lesser amount of IGF-I, and low amounts of IGFBPs, which play a critical role in the autocrine/paracrine control of cell growth. Among different cell lines available in our laboratory, we finally selected these human cells on the basis of their peculiar pattern of neuroepetide receptor expression (see below). In this study, we used CALU-6 cells, already characterized in our laboratory for IGF autocrine stimulating pathways (9, 14), to investigate: 1) the expression of SSR and DR subtypes, 2) the effects on cell proliferation of two new SS/DA chimeric molecules (BIM-23A370 and BIM-23A387) with the ability to bind both sst 2 and D 2 R with high affinity as compared with the effect of experimental and clinically available SSA and DA agonists; 3) the effects of chimeric molecules on the production and expression of IGF system components.
Briefly, we attempted to ascertain whether SS/DA chimeric compounds, either directly or via modification of the IGF system, influence the differentiation and proliferation of this cell line, and whether this cells, constitutively expressing SSR and DR, may represent a suitable model to further investigate neuropeptide receptor cross-talk and regulation.
MATERIALS AND METHODS

Products
BIM compounds, including lanreotide, were provided by Biomeasure, Inc. (Milford, MA, USA). BIM-23A370 and BIM-23A387 are chimeric molecules that combine structural elements of both SS and D and retain affinity for both the sst 2 and D 2 R. BIM-23023 is an sst 2 -preferential compound, whereas BIM-53097 is a D 2 R-preferential compound, which served as control peptides for chimeras (28). BIM-23206 is an sst 5 -preferential compound, whereas BIM-23244 is a bi-specific sst 2 /sst 5 -preferential ligand (27). The IC 50 values for BIM compounds are reported in Table 1 . The DA agonist, cabergoline, was kindly provided by Pharmacia, while SS-14 was purchased from Bachem Inc., Hanover, Germany.
Cell cultures
Cells were grown in MEM supplemented with 10% fetal calf serum, 1% non-essential amino acids, 20 mg/dl gentamycin, 200 mM glutamine, and 1 mM sodium pyruvate till subconfluence. Different cultures were settled for functional studies in MEM serum-free medium supplemented with 0.1% BSA. CALU-6 cells (1x10 4 
IGF-II and IGFBP secretion
After 18 h in serum-free medium, CALU-6 cells were incubated in fresh medium with or without SS/DA chimeric compounds and control peptides at a concentration of 10 -8 M. After 24 h, conditioned medium was collected and dialyzed against 1 M acetic acid. IGFs were separated from IGFBPs by gel filtration on a FPLC Superdex-75 column equilibrated with 0.1 M acetic acid-0.15 M NaCl. IGF content was evaluated in the eluted fractions in the mol. wt. range of the free peptide, whereas the IGFBP content was evaluated in the fractions eluted in the molecular mass range of more than 20 kDa by appropriate immunoassay, as already reported (6).
RT-PCR studies
RT-PCR for SSR and DR was performed as previously described (4) . Briefly, poly A+ mRNA was isolated using Dynabeads Oligo (dT)25 (Dynal AS, Oslo, Norway) from cell pellets containing 1-2x10 6 cells per sample. cDNA was synthesized using the poly A+ mRNA captured on the Dynabeads Oligo For the IGF system components, RNA extraction and RT-PCR were performed only for IGF-II and IGFBP-2, the two components mainly expressed by this cell line, as already described (17) . 
Statistical analysis
Statistical analysis was performed by parametric ANOVA for unpaired samples and area under the curve computation (AUC) followed by ANOVA and t-test. P<0.05 was considered significant. Results are expressed as the mean ± SEM. To minimize variation among different experiments, the results are expressed as relative variation from untreated control value ( value).
RESULTS
Somatostatin and dopamine receptor subtype expression and regulation
The expression of sst 2 , sst 3 , sst 5 (0.5 sst 5 / -Gus) was relatively higher than that of sst 2 (0.008 sst 2 / -Gus), whereas the expression of sst 3 was very low (0.001 sst 3 / -Gus).
Functional studies
These studies were performed to test the effects of the chimeric compounds, the control peptides for the chimeras, SSR subtype-preferential compounds, as well as SS-14, cabergoline and lanreotide on CALU-6 cell proliferation and production of IGF/IGFBP peptides.
Cell proliferation. All tested substances significantly inhibited cell proliferation, as measured by cell counting (data not shown) and by 3 H-Thymidine incorporation, but to different extents (p<0.0001). The analogs have not a significant effect at all concentration tested but that curves were different and the concentrations significantly affected the result. Results from the doseresponse experiments are illustrated in Figure 3 . Both chimeras, BIM-23A370 and BIM-23A387, resulted significantly more potent in inhibiting cell proliferation compared to all the other compounds, tested alone or in combination, including SS-14, the sst 2 -preferential compound BIM-23023 and the D 2 R-preferential compound BIM-53097 (controls for the chimeras).
Moreover, the BIM-23A370 was significantly more potent than the other chimera, BIM-23A387 (Fig. 4) . SS-14 was significantly more effective in inhibiting 3 H-Thymidine incorporation compared to lanreotide, the sst 2 -and sst 5 -preferential compounds BIM-23023 and BIM-23206, alone or combined, cabergoline, the combination of the sst 2 -and D 2 R-preferential compounds BIM-23023 and BIM-53097, whereas it was not significantly different from the bi-specific sst 2 /sst 5 analog BIM-23244 and to the combination of cabergoline plus lanreotide. These results, obtained after the calculation of the AUCs, are summarized and better detailed, expressed in decremental areas with all the p values, in Figure 4 .
IGF system secretion and expression
The BIM-23A370 chimera, as well as the DA and SS controls, BIM-23023 and BIM-53097, were ineffective in modulating either the expression or the secretion of IGF and IGFBP peptides in cultured CALU-6 cells (data not shown). Figure 6 shows the lack of effect of chimera and control peptides on IGF-II and IGFBP-2 mRNA expression, the main IGF and IGFBP peptides produced by CALU-6 cells.
DISCUSSION
The co-administration of SSA and DA is considered more effective than treatment with either drug alone in suppressing GH secretion and normalizing circulating IGF-I levels in a minority of acromegalic patients (3, 5, 10, 11). These are mainly patients bearing mixed pituitary tumors that co-secrete both GH and PRL. These tumors are known to express a higher number of DR on heterodimerization resulted in the inactivation of sst 3 (19) . However, apart from preliminary data in rat neuronal cells (1), receptor dimerization has so far been observed only in transfected cell systems, and the significance and the properties of the dimeric form of these receptors has never been clarified.
In the present study, we investigated a human tumor cell line constitutively expressing both SSR and DR. In particular, we demonstrated the presence of sst 2 , and sst 5 , together with D 2 R and to a lesser extent sst 3 and D 4 R, at both the nucleotide and protein levels in the CALU-6 NSCLC line.
We therefore focused our attention upon the two specific receptor subtypes already established to be involved in receptor dimerization, namely sst 2 and D 2 R. We studied the effects of different compounds with specific binding profiles, including chimeric molecules which selectively bind both sst 2 and D 2 R, on cell proliferation and on the IGF system autocrine pathway.
In dose-response studies, both chimeric compounds, BIM-23A370 and BIM-23A387, were found to be significantly more potent in inhibiting cell proliferation than specific sst 2 -and sst 5 -preferring and D 2 R-preferring analogs, tested both alone and in combination, and than sst 2 /sst 5 bispecific SSA and native SS-14. As already suggested for the regulation of GH and PRL secretion from pituitary tumors, the enhanced potency of chimeric molecules seems to be related to the intrinsic characteristics of these drugs, which retain both somatostatinergic and dopaminergic pharmacological properties. It is intriguing that the lower inhibitory activity of SS-14 and sst 2 -, sst 5 -and D 2 R-preferential ligands, including lanreotide and cabergoline, on cell growth is in line with the very low expression of their related SSR and DR subtypes, whereas the chimeric molecules strongly affect cell proliferation. Indeed, the inhibitory activity of one chimera, BIM-23A370, was higher than that of the other, and even more pronounced when compared with the SS-14 and with the currently available SSA and DA lanreotide and cabergoline, tested alone and in combination.
As CALU-6 cell growth is regulated by an autocrine pathway involving specific components of the IGF system (9, 14), in particular IGF-II, we evaluated the effects of the more potent chimera, BIM-23A370, and its control peptides, the sst 2 -preferring analog, BIM-23023, and the D 2 Rpreferring analog, BIM-53097, on the secretion and synthesis of IGFs and IGFBPs; there was no effect whatever. The results of these experiments exclude an IGF-mediated inhibition of cell growth for SSA, DA and the SS/DA chimeric compounds. On the basis of their affinity profile, we currently have no explanation for the enhanced potency of the chimera BIM-23A370, as compared with the other chimera, BIM-23A387. However, conformational differences, stability and altered ability to induce receptor activation and/or cooperation cannot be ruled out.
Excluding both chimeras, the next most potent compound resulted SS-14, and this evidence might be explained by the SS-14-induced recruitment of additional SSR subtypes, namely sst 3 and sst 5 , which are also co-expressed in these cells, or, even more interesting, by a ligand-induced SSR dimerization. The evidence that the bi-specific sst 2 /sst 5 SSA BIM-23244 displayed a higher potency in inhibiting cell proliferation than lanreotide, as well as the sst 2 -and sst 5 
